GOSS vs UTHR

Gossamer Bio (GOSS) remains a high-risk, high-reward biotech opportunity, primarily driven by its lead asset, GB004 (seralutinib), for Pulmonary Arterial Hypertension (PAH). The significant positive Phase 2 TORREY study results, announced in late 2024, substantially de-risked the asset, validating its potential as a first-in-class, oral treatment in a market with high unmet needs. This solidifies ...

United Therapeutics continues to build on its strong foundation in rare pulmonary diseases with significant recent wins. The TETON-1 pivotal study success for Tyvaso in IPF substantially expands its addressable market and derisks future revenue streams from its core business. Furthermore, the FDA's RMAT designation for miroliverELAP provides a positive signal for its ambitious regenerative medicin...